ArticleJournal of translational medicine2026
Nicotine promotes cardiac fibrosis by regulating miR-125b-5p maturation via HNRNPA2B1-mediated METTL14-dependent m⁶A methylation: therapeutic reversal by cinacalcet HCl.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCardiac fibrosis is a pivotal pathological process driving adverse cardiac remodeling and a defining feature of end-stage heart disease. Nicotine, a principal constituent of tobacco products, is now recognized as an independent risk factor for cardiovascular disease. However, its direct effects on cardiac fibroblasts (CFs) biology and the molecular mechanisms underlying nicotine-induced cardiac fibrosis remain incompletely understood.
methodsPrimary CFs and a rat model of nicotine exposure were used to access the pro-fibrotic effects of nicotine. Drug affinity responsive target stability (DARTS) and cellular thermal shift assay (CETSA) were employed to identify the cellular targets of nicotine. Methylated RNA immunoprecipitation (MeRIP), RNA immunoprecipitation (RIP) and quantitative real-time PCR (qRT-PCR) were used to quantify m⁶A modification and microRNA biogenesis. miR-125b-5p overexpression or inhibition, heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1, abbreviated as A2B1 in all figures) silencing, and pharmacological inhibition with cinacalcet HCl were performed both in vitro and in vivo to evaluate the impact of this signaling axis on nicotine-induced fibrotic phenotypes. Collagen deposition, CFs proliferation, and activated transforming growth factor-β1 (TGF-β1)/Mitogen-Activated Protein Kinase (MAPK) signaling were assessed by histology, immunoblotting, and immunofluorescence.
resultsNicotine promoted CFs proliferation and migration, myofibroblasts (MFs) transformation, and collagen accumulation. HNRNPA2B1 was identified as a potential binding target of nicotine. Mechanistically, nicotine up-regulated methyltransferase-like 14 (METTL14), thereby increasing m⁶A methylation of pri-miR-125b. HNRNPA2B1 recognized methylated pri-miR-125b, facilitated its interaction with DiGeorge Syndrome Critical Region 8 (DGCR8), and thereby accelerated miR-125b-5p maturation. Elevated miR-125b-5p suppressed p53 and activated the TGF-β1/MAPK axis, driving cardiac fibrosis. Knockdown of HNRNPA2B1 or treatment with cinacalcet HCl markedly reduced the levels of miR-125b-5p and ameliorated nicotine-induced cardiac fibrosis in vitro and in vivo.
conclusionsNicotine induces excessive maturation of miR-125b-5p through an m⁶A-dependent, HNRNPA2B1-mediated mechanism, thereby promoting cardiac fibrosis. Targeting this signaling pathway—either genetically or pharmacologically with cinacalcet HCl—effectively attenuates fibrotic remodeling, providing a novel mechanistic rationale and potential therapeutic strategy management of cardiac fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.